QQ客服 官方微博 反馈留言

浏览/检索结果: 共16条，第1-10条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression 期刊论文 2019, 卷号: 145, 期号: 6, 页码: 1569-1579 作者:  Schuler, Martin;  Tan, Eng-Huat;  O'Byrne, Kenneth;  Zhang, Li;  Boyer, Michael 收藏  |  浏览/下载：20/0  |  提交时间：2020/01/03 Afatinib  EGFR  NSCLC  Dose adjustment  Time-to-treatment failure   2017 Multimodality Appropriate Use Criteria for Noninvasive Cardiac Imaging: Expert Consensus of the Asian Society of Cardiovascular Imaging 期刊论文 2017, 卷号: 18, 期号: 6, 页码: 871-880 作者:  Beck, Kyongmin Sarah;  Kim, Jeong A.;  Choe, Yeon Hyeon;  Hian, Sim Kui;  Hoe, John 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 Appropriate use criteria  Multimodality  Noninvasive cardiac imaging   Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer 期刊论文 2017, 卷号: 2, 期号: 3, 页码: e000219 作者:  Blackhall Fiona;  Ross Camidge D;  Shaw Alice T;  Soria Jean-Charles;  Solomon Benjamin J 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 Alk  clinical trial  crizotinib  profile 1005   First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 期刊论文 2017, 卷号: 12, 期号: 1, 页码: S335-S336 作者:  Park, Keunchil;  Tan, Eng Huat;  Zhang, Li;  Hirsh, Vera;  O'Byrne, Ken 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03 afatinib  gefitinib  NSCLC  EGFR   Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease 期刊论文 2017, 卷号: 377, 期号: 14, 页码: 1319-1330 作者:  Eikelboom, J. W.;  Connolly, S. J.;  Bosch, J.;  Dagenais, G. R.;  Hart, R. G. 收藏  |  浏览/下载：63/0  |  提交时间：2020/01/03 Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial 期刊论文 2016, 卷号: 17, 期号: 5, 页码: 577-589 作者:  Park, Keunchil;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li;  Boyer, Michael 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04 Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) 期刊论文 2016, 卷号: 12, 期号: 1, 页码: 1-222 作者:  Klionsky, Daniel J.;  Abdelmohsen, Kotb;  Abe, Akihisa;  Abedin, Md Joynal;  Abeliovich, Hagai 收藏  |  浏览/下载：26/0  |  提交时间：2020/01/04 autolysosome  autophagosome  chaperone-mediated autophagy  flux  LC3  lysosome  macroautophagy  phagophore  stress  vacuole   First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/04 First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04 IMPACT OF CRIZOTINIB TREATMENT ON PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (QOL) IN ASIAN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) 期刊论文 2012, 卷号: 7, 期号: 11, 页码: S491-S491 作者:  Shi, Yuankai;  Iyer, S.;  Kim, Dong-wan;  Reisman, A.;  Liu, Xiaoquing 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13 crizotinib  Patient-reported outcomes  NSCLC  quality of life